A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.
Latest Ratings for LUCD
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2021 | Ascendiant Capital | Initiates Coverage On | Buy | |
| Dec 2021 | Needham | Maintains | Buy | |
| Nov 2021 | BTIG | Initiates Coverage On | Buy |
